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Background: This phase II study describes the efficacy and safety of combination chemotherapy of 5-fluorouracil
(5-FU), low-dose leucovorin, and oxaliplatin (FLOX regimen) for pretreated advanced gastric cancer.
Patients and methods: Patients who had been previously treated with greater than or equal to one regimen were
enrolled. Patients received an oxaliplatin 75 mg/m2 on day 1, 5-FU 1000 mg/m2 on days 1–3, and leucovorin 20 mg/m2
on days 1–3, every 3 weeks. The primary end point was overall survival (OS).
Results: Among the 52 patients enrolled, 26 patients were treated as second line, and the remaining 26 patients
were enrolled as third- or fourth line. A total of 203 cycles of chemotherapy were administered with the median
being three cycles (range 1–15) per patient. The median OS was 6.6 months [95% confidence interval (CI) 4.5–8.8] and
the median progression-free survival was 2.5 months (95% CI 1.9–3.0). The response rate was 4% (95% CI 0–9%),
and the disease control rate was 48% (95% CI 34–62%). The most common toxic effects of grade 3/4 were
neutropenia (16%) and vomiting (6%).
Conclusions: The FLOX regimen showed modest activity as a salvage treatment in pretreated advanced gastric
cancer with a favorable compliance.
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introduction
Gastric cancer is a leading cause of cancer deaths worldwide; it
ranks second in global cancer mortality following lung cancer
[1]. In gastric cancer, the prolongation of patients’ survival and
improvement of the quality of life are challenges for the
oncologists. Gastric cancer is considered to be moderately
chemotherapy responsive, and combination chemotherapy is
the standard approach in the treatment of metastatic gastric
cancer. For first-line chemotherapy, many combination
regimens have shown a response rate of 35%–45%. The median
progression-free survival (PFS) has been 5–6 months, which
means many patients eventually develop progressive disease
(PD). Recent advances in chemotherapy have enabled many
patients to maintain good performance status (PS) after first-
line chemotherapy. There is an urgent need for second-line or
even third-line salvage chemotherapy. Until now, there has
been no standard second-line chemotherapy, although various
chemotherapy regimens have been tried [2]. Cisplatin-based
regimens have shown response rates of 19%–45% [3–5];
paclitaxel-based regimens have shown response rates of
22%–27% [6, 7]; and irinotecan-based regimens have shown
response rates of 27%–52% [8, 9]. However, antitumor
responses and response durations were heterogeneous among
regimens, depending on the previous chemotherapy, and
considerable toxicity accompanied most of these regimens.
Therefore, survival prolongation while maintaining good
clinical conditions should be the goals of salvage chemotherapy
in pretreated gastric cancer.
Oxaliplatin is a third-generation platinum compound that
acts as an alkylating agent, inhibiting DNA replication by
forming guanine adducts [10]. Oxaliplatin has been shown to
exhibit antitumor activity against cancer cell lines with acquired
cisplatin resistance as well as clinical tumors that are
intrinsically resistant to cisplatin and carboplatin [11, 12]. Only
a few studies of oxaliplatin in the treatment of advanced gastric
cancer are available. In regard to first-line chemotherapy in
phase II studies, some combinations of oxaliplatin with 5-
fluorouracil (5-FU) have shown a response rate and overall
survival (OS) of 40% and 10 months, respectively [13–15].
These combinations showed low incidences of grade 3/4 toxic
effects. The FOLFOX regimen also has some activity in
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cisplatin-pretreated patients. On the basis of these data, we
planned a 5-FU, low-dose leucovorin, and oxaliplatin (FLOX)
regimen that involves oxaliplatin combined with continuous
infusion of 5-FU and low-dose leucovorin as salvage treatment
for those who had failed previous chemotherapy treatments.
patients and methods
patient eligibility
Patients with histologically confirmed recurrent or metastatic gastric
adenocarcinoma were considered eligible when they met all the following
criteria: (i) age ‡18 years; (ii) Eastern Cooperative Oncology Group
(ECOG) performance scale £2; (iii) evaluable disease with or without
measurable lesions; (iv) disease progression after previous chemotherapies
within 3 months before entry, with the maximum number of previous
regimens being three in total, including neo-adjuvant or adjuvant
chemotherapy; and (v) adequate hematological, renal, and hepatic
functions. The latter was defined as neutrophil ‡1500/ll, platelet ‡100 000/ll,
serum creatinine £1.5 mg/dl, total bilirubin £1.25 (or 1.5) · upper limit of
normal (ULN) in the absence (or presence) of liver metastasis, and serum
transaminase £2.5 (or 5.0) · ULN in the absence (or presence) of liver
metastasis. Patients were excluded if they had concurrent malignancy
within the past 5 years (excluding basal cell carcinoma of the skin or
cervical carcinoma in situ), peripheral neuropathy as determined by the
National Cancer Institute common toxicity criteria (NCI—CTC) grade ‡2,
symptomatic metastasis to central nervous system, or uncontrolled
significant comorbid conditions. All patients gave informed consent before
enrollment.
treatment
Chemotherapy consisted of an i.v. injection of a bolus of leucovorin 20 mg/
m2 on days 1–3 and continuous i.v. infusion of 5-FU 1000 mg/m2 on days
1–3. Oxaliplatin was administered at 75 mg/m2 as a 2-h infusion on day 1
before the start of leucovorin and 5-FU infusion. The cycle was repeated
every 3 weeks. Patients were premedicated with routine antiemetics. In
the case of hematologic toxicity, the next cycle was delayed until the
recovery of the neutrophil count ‡1500/ll and platelet count ‡100 000/ll.
Prophylactic use of granulocyte-colony stimulating factor (G-CSF) was not
allowed, but G-CSF was indicated when patients developed grade 4
neutropenia. The dose of oxaliplatin and 5-FU was reduced by 20% for
subsequent courses if greater than or equal to grade 4 hematologic or
greater than or equal to grade 3 nonhematologic toxicity occurred in the
previous cycle. Dose reescalation was not allowed. Patients who required >4
weeks of rest for recovery from any toxicity other than alopecia or anemia
or who required dose reduction of more than one step (20% from initial
dose) were withdrawn from the study. Chemotherapy was continued until
there was disease progression, occurrence of unacceptable toxicity, or the
patient withdrew from the study.
patient evaluation
Baseline evaluations included a complete medical history with physical
examination, PS, complete blood count (CBC), serum chemistries,
carcinoembryonic antigen (CEA), urine analysis, creatinine clearance, and
electrocardiography. A radiological examination of each lesion was done
within 3 weeks before the treatment. Fiberoptic gastroduodenoscopy and
positron emission tomography were planned for the evaluation of complete
responders of all evaluable lesions.
A physical examination, PS, CEA, and laboratory evaluation (CBC,
serum chemistries, and urinalysis) were evaluated before each subsequent
cycle. For tumor response evaluation, imaging studies were repeated every
two cycles. Treatment response was evaluated using spiral computed
tomography according to the guidelines of the Response Evaluation Criteria
in Solid Tumors Committee. The response was analyzed by intention-to-
treat (ITT) analysis. Patients were considered to be assessable for response
when they had received a minimum of two cycles of treatment with at least
one tumor measurement or when they had evidence of early disease
progression clinically or radiologically within two cycles. All the patients
were evaluated for adverse events from the time of their first treatment
cycle. Adverse events were evaluated weekly and recorded as a grade
according to the NCI—CTC (version 3.0) for each patient. PFS was defined
from the start of the treatment to the disease progression or death of any
cause, and OS was calculated from the treatment start to death of any cause.
biostatistics
The primary aim of this study was to test the hypothesis that OS would
improve by 50% compared with historical controls. The study was designed
to have a 90% power to show an improvement in OS from 3.5 to 5.3
months with a 10% type I error, using two-sided testing, and assuming
exponential OS times. According to Minimax phase II design, a sample size
of 47 patients was required. Considering a 10% drop out rate, 52 patients
were needed for this trial. The secondary aims included response rate,
safety, PFS, and 1-year survival rate. Time-dependent variables were
analyzed using the Kaplan–Meier method and compared using the log-rank
test. Multivariate analysis was carried out using Cox proportional hazards
regression model. Exact 95% confidence interval (CI) was provided for
proportions.
results
patient characteristics
From April 2004 to May 2007, a total of 52 patients were
enrolled, and all but one patient were assessable for tumor
response. One patient was excluded from the study because he
refused radiological examination after two cycles of
chemotherapy. Patient characteristics are summarized in Table
1. The median age was 58 years. Twenty-six patients (50%) got
FLOX as second-line treatment, and 26 patients (50%) got
FLOX as third- or fourth-line treatment. Twenty-four patients
(46%) had prior gastrectomy, among whom 16 patients (31%)
got curative resection. The main metastatic sites were the
peritoneum (n = 28), abdominal lymph nodes (n = 27), and
liver (n = 15). Median value of the prechemotherapy level of
CEA was 2.7 (range 0.2–11,531 ng/ml).
Previous chemotherapy histories of our patients are
summarized in Table 2. The median cycle number of previous
first-line chemotherapy was 6 (range 2–16 cycles) with
a median dose intensity of 0.95 (range 0.57–1.0). The overall
response rate of first-line chemotherapy was 31%. Twenty-six
patients received second-line chemotherapy with the median
number of cycles being 4 (range 1–9). The median dose
intensity was 1.0 (range 0.6–1.0). Overall response rate of
previous second-line chemotherapy was 22%. The median cycle
number of previous third-line chemotherapy in eight patients
was 4 (range 2–10). With a median dose intensity of 1.0 (range
0.87–1.0), the overall response rate was 13%. This implies that
the patients enrolled in this study got enough doses and cycles
of previous chemotherapy.
treatment summary
Treatment is summarized in Table 3. A total of 203 cycles
were administered, with a median of three cycles (range 1–15)
per patient. The median dose intensity of oxaliplatin was
original article Annals of Oncology
1136 | Jeong et al. Volume 19 | No. 6 | June 2008
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on Septem
ber 4, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
25 mg/m2/week (range 15–29 mg/m2/week), and the median
intensity of 5-FU was 324 mg/m2/week (range 196–351 mg/m2/
week). The relative dose intensity of oxaliplatin and 5-FU were
0.97 and 0.98, respectively. Four patients were subjected to dose
reduction due to grade 3 nonhematologic toxic effects: liver
enzyme elevation, mucositis, peripheral neuropathy, and
nausea, respectively. Twenty-five total cycles were delayed in
14 patients (27%) due to liver enzyme elevation (n = 1),
infection (n = 1), mucositis (n = 1), and by patients’ preference
(n = 11). After PD on this regimen, 17 patients of second-line
treatment (65%) were transferred to the third-line salvage
chemotherapy: taxane monotherapy (n = 7), cisplatin plus
irinotecan (n = 9), and 5-FU agents (n = 1). Six patients (23%)
who receive FLOX regimen as the third- or fourth line were
transferred to further salvage chemotherapy: taxane
monotherapy (n = 3), oral 5-FU agents (n = 1), and cisplatin
plus irinotecan (n = 2).
efficacy
With a median follow-up duration of 6 months (range 1–17
months), 48 patients had disease progression, and 41 patients
(85%) died from cancer progression.
The median OS was 6.6 months (95% CI 4.5–8.8 months).
When we evaluated the OS according to the previous
treatment, OS was 6.6 months (95% CI 3.4–9.8 months) for the
second-line treatment group and 6.4 months (95% CI 3.9–8.8
months) for greater than or equal to third-line treatment group
(P = 0.506) (Figure 1).
One-year survival rate of all patients was 30% (38% for the
second-line group, 21% for the third-line group, and 0% for
the fourth-line group). The median PFS was 2.5 months (95%
CI 1.9–3.0 months) by ITT analysis. When we evaluated the
PFS according to the previous treatment, it was 3.0 months
(95% CI 0.8–5.2 months) for the second-line treatment group
and 2.3 months (95% CI 1.0–3.6 months) for greater than or
equal to third-line treatment group (P = 0.167) (Figure 2).
When we compared survival according to clinical parameters
by multivariate analysis, only initial CEA level (£5.0 ng/ml)
(P = 0.020) was a favorable factor for OS, and a good ECOG PS
(£1) (P = 0.078) showed a favorable trend for longer survival.
For PFS, only initial CEA level (£5.0 ng/ml) (P = 0.038) was
a significant favorable factor.
Response to therapy was assessable in all but one patient,
who withdrew after the second cycle without any response
evaluation. The overall objective response rates are
summarized in Table 4. Of the 52 assessable patients, 2
achieved a partial response (PR) and 23 patients had stable
disease (SD). The overall response rate was 4% (95% CI 0–9%),
and the disease control rate (DCR) was 48% (95% CI 34–62%).
The two patients who achieved PR had received cisplatin
as their first-line treatment. Their response duration was
15.8 and 3.6 months.
DCR was evaluated separately by the previous treatment as
post hoc analysis. Among the 26 patients receiving second-line
Table 1. Patient characteristics
Characteristics Number of
patients
%
Number of enrolled patients 52
Number of assessable patients 51
Number of patients with
measurable lesion
43 83
Sex
Male 34 65
Female 18 35
Age (median), years 58 (37–75)
ECOG
0–1 23 45
2 29 56
Histology
Well to moderately
differentiated
15 29
Poorly differentiated 24 46
Signet ring cell 8 15
Unknown 5 10
Number of previous chemotherapy regimen
1 26 50
2 18 35
3 8 15
Previous operation
Unresectable 28 54
Radical 16 31
Palliative 8 15
Number of metastatic sites
1 12 23
2 20 39
‡3 20 38
Disease site
Abdominal lymph nodes 27 52
Peritoneum 28 54
Liver 15 29
Lung 5 10
Bone 6 12
Ovary 2 4
ECOG = Eastern Cooperative Oncology Group.
Table 2. Summary of prior chemotherapy history
Treatment group Number of
enrolled
patients
Median
cycle
(range)
Median
RDI
(range)
First line 52
Cisplatin based 17 6 (2–16) 0.9 (0.57–1)
Others1 35 8 (2–12) 0.97 (0.59–1)
Second line 26
Cisplatin based 3 9 (2–9) 0.98 (0.77–1)
Others2 23 4 (1–9) 1 (0.6–1)
Third line 8
Cisplatin based – – –
Others3 8 4 (2–10) 1 (0.87–1)
15-FU + leucovorin + taxotere, 5-FU + leucovorin + taxol, S-1, capecitabine +
doxorubicin, taxol + S-1, 5-FU + doxoribicin, taxotere + S-1, taxotere +
capecitabine, herceptin + cisplatin + capecitabine.
25-FU + leucovorin + taxol, S-1, capecitabine + doxorubicin, capecitabine,
taxol, sutene.
3Capecitabine, capecitabine + doxorubicin, S-1, taxol.
RDI, relative dose intensity.
Annals of Oncology original article
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treatment, the DCR was 58% (95% CI 37–78%). The median
duration of SD was 3.9 months (range 0.9–12.4 months). Of
the 26 patients in the greater than or equal to third-line
treatment group, the DCR was 38% (95% CI 18–59%), and the
median duration of SD was 2.3 months (range 1.4–6.9).
toxicity
The toxicity profile is summarized in Table 5. There was no
case of treatment-related mortality. The most common grade
3/4 hematologic toxicity was neutropenia, which was found in
16% of patients. Leukopenia and anemia of grade 3/4 were also
observed in 8% and 4% of the patients, respectively. Twenty-
three patients required G-CSF support, but none of them
suffered febrile neutropenia. The median frequency of G-CSF
administration of all the patients was 2 (range 1–10). Nineteen
patients received a transfusion. The median unit of red blood
cell transfused was 2 packs (range 1–6).
The most common grade 3 nonhematological toxic effects
were vomiting (6%), nausea (4%), and mucositis (4%). Grade
3 peripheral neuropathy was observed in two patients (4%).
Using Fisher’s exact test, we compared the incidence of grade 3/
4 toxicity between the second-line treatment group and greater
than or equal to third-line treatment group. There were no
significant differences in the incidence of neutropenia,
vomiting, or peripheral neuropathy between the two groups.
discussion
There are no randomized controlled trials that have indicated
a benefit of the second-line chemotherapy compared with
supportive care alone. But responders to second-line
chemotherapy survive longer compared with nonresponders,
and symptomatic benefit may be obtained from the second-line
therapy [2]. This study evaluated the clinical feasibility of
oxaliplatin combined with 5-FU in previously treated patients
with advanced gastric cancer. In this study, we adopted
oxaliplatin 75 mg/m2 instead of oxaliplatin ‡85 mg/m2. We did
this because more patients were expected to receive this
regimen as the third- or fourth line of treatment. Therefore, we
assumed that a lower dose of oxaliplatin would be reasonable
considering patient safety and tolerability.
The oxaliplatin, 5-FU, and leucovorin combination is
accepted in patients who are refractory to 5-FU and leucovorin
in colorectal cancer [16]. This combination (FOLFOX) is on
the basis of a bimonthly schedule, and the response rate of
various combinations of FOLFOX is 20%–46%. Recently,
oxaliplatin in various combinations with 5-FU and leucovorin
were tried as first-line treatments for advanced gastric cancer,
and the reported response rates were 38%–45% [13–15]. On
the contrary to colorectal cancer, in vitro antitumor activity is
reported to have a strict sequence dependency of oxaliplatin
followed by 5-FU in gastric cancer, which was the basis of our
protocol development [17].
The other point to mention is that, in this study, the primary
end point was OS. However, in advanced gastric cancer with
prior treatment, the traditional measured primary end point
of phase II study is response rate, which is poorly correlated
with patients’ survival. A recent Japanese study demonstrated
that the response of a primary gastric mass is poorly
correlated with that of a metastatic lesion [18]. Moreover,
gastric cancer often progresses as nonmeasurable disease.
Locoregional or peritoneal metastasis comprises 50% of the
initial recurrence of gastric cancer in Korean patients, most
of which cannot be assessed by conventional imaging [19].
Therefore, we concentrated on survival rather than response
rate to measure the clinical benefit of the salvage
chemotherapy in previously treated patients. When we initiated
this study, most of studies of the second-line treatment of
advanced gastric cancer after failing previous active
combination chemotherapy reported the median survival
time of 2.5–5.0 months [3, 4,20–23]. This is underestimated
considering a recent pooled analysis reported in American
Society of Clinical Oncology Gastrointestinal Symposium
2004 (5.6 months). However, on designing this trial, patients
Figure 1. Analysis of overall survival according to previous treatments.
Figure 2. Analysis of progression-free survival according to previous
treatments.
original article Annals of Oncology
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were allowed to receive not only second-line treatment but also
third- or fourth-line treatment of oxaliplatin. Moreover, we
anticipated considerable patients of modest PS (ECOG grade 2)
to be enrolled. Therefore, we assumed that the historical
control of 3.5 months could be a reference. Our study was
designed to prove an increment of OS by 50% to 5.3 months.
We thought this was somewhat high considering the patients’
general condition and prior exposure to chemotherapy.
Nevertheless, we believe that this survival parameter is currently
the minimum range for acceptance of any new regimen aiming
at second- or third-line treatment of gastric cancer [20, 21, 23].
In this study, the median OS was 6.6 months (95% CI 4.5–8.8).
We can presume that good PS maintained throughout the
treatment duration enabled many patients to be transferred to
another chemotherapy regimens.
The third point to consider is that overall response rate was
only 4% with 48% DCR. Toxicity, especially nonhematologic
toxicity, however, was quite low. Toxicity profile and its
incidence did not show any differences between the second-line
group and greater than or equal to the third-line treatment
group. Kim et al. [24] reported the OFL-CL regimen
(oxaliplatin 85 mg/m2 and infusion of high-dose 5-FU and
leucovorin) with a response rate of 26% and median survival of
7.3 months in patients previously treated with platinum.
Schmid et al. [22] combined oxaliplatin 130 mg/m2 with
thymidylate synthase inhibitor, raltitrexed, as second-line
treatment, but its response rate was only 5% and median
survival was 4.5 months [25]. Although there is little evidence
that a higher oxaliplatin dose guarantees higher response rate,
we think our poor response can be explained by the fact that
half the patients got FLOX regimen as third- or fourth-line
treatment with high tumor burden. Moreover, we can also
indicate that the FLOX regimen could be recommended for
previously cisplatin-exposed patients because two responders
had previous cisplatin treatment; this is consistent with
a previous study [24]. PS, retreatment after failure of
a nonplatinum-based regimen, and previous response with
first-line therapy are known predictive factors for response to
second-line chemotherapy [2]. These factors, however, were
not correlated with PFS or OS in our study. Neither PFS nor
OS was affected by previous exposure to cisplatin. Therefore,
we could indicate that the FLOX regimen is also an acceptable
option in terms of patient survival for salvage chemotherapy in
pretreated patients.
Table 3. Treatment summary and dose intensity
Treatment group Total
patients (n = 52)
Second
line (n = 26)
Third
line (n = 18)
Fourth
line (n = 8)
Treatment cycle
Median (range) 3 (1–15) 4 (1–12) 2 (1–15) 3 (1–4)
Treatment delay
Total cycle 203 123 59 21
Delayed cycle 25 15 4 3
Median delayed week 1 (1–3) 2 (1–3) 1 (1–3) 2 (1–3)
Number of dose
modification (cycle)
14 10 1 3
Median dose intensity mg/m2//week (range)
5-FU 324 (196–351) 314 (227–342) 333 (283–351) 311 (196–333)
Oxaliplatin 25 (15–29) 24 (17–26) 25 (21–29) 23 (15–25)
Relative dose intensity (range)
5-FU 0.97 (0.59–1) 0.94 (0.68–1) 1 (0.85–1) 0.93 (0.59–1)
Oxaliplatin 0.98 (0.59–1) 0.94 (0.68–1) 1 (0.85–1) 0.93 (0.59–1)
5-FU, 5-fluorouracil.
Table 4. Response evaluation by intention-to-treat analysis
Number of total
patients (n = 52)
Second-line
treatment (n = 26)
Third- and fourth-line
treatment (n = 26)
Measurable
(n = 43)
Nonmeasurable
(n = 9)
Measurable
(n = 20)
Nonmeasurable
(n = 6)
Measurable
(n = 23)
Nonmeasurable
(n = 3)
Complete response – – – – – –
Partial response 2 – 1 – 1 –
Stable disease 18 5 10 4 8 1
Progressive disease 22 4 8 2 14 2
NA 1 – 1 – 0 –
ORR (%) 5 5 4
DCR (%) 47 55 39
NA, not available; ORR, overall response rate; DCR, disease control rate.
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One of the main adverse effects of oxaliplatin is peripheral
neuropathy. The cumulative dose of oxaliplatin (>540 mg/m2)
is an important factor in the development of peripheral
neuropathy [25]. Even considering 20 (38%) cisplatin-
pretreated patients in our study, neuropathy of grades 2–3 was
noticed in only five patients. This may be due to a low
cumulative dose of oxaliplatin (median 175 mg/m2). Severe
diarrhea and stomatitis were rare. Nausea and vomiting were
the most common nonhematological toxicity, which was
consistent with other reports. In conclusion, using the FLOX
regimen, high DCR prolonged OS. Furthermore, its lower
toxicity and preserved PS made many patients (n = 23, 48%)
eligible for the next regimen. This FLOX regimen afforded
a comparable survival profile and acceptable toxic effects in
pretreated patients of advanced gastric cancer. Randomized
clinical trial is needed to clarify if this regimen can be applied as
salvage chemotherapy.
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Table 5. Toxicity profiles per patient (n = 52) according to the
NCI—CTC grade (version 3.0)
Grade
1
Grade
2
Grade
3
Grade
4
Grade
3/4 (%)
Hematologic toxicity
Anemia 22 25 2 (4) – 2 (4)
Neutropenia 5 11 6 (12) 2 (4) 8 (16)
Thrombocytopenia 9 3 – – –
Nonhematologic toxicity
Diarrhea 8 1 1 (2) – 1 (2)
Anorexia 8 5 1 (2) – 1 (2)
Nausea 6 6 2 (4) – 2 (4)
Vomiting 6 4 3 (6) – 3 (6)
Mucositis 12 1 2 (4) – 2 (4)
Constipation 3 2 – – –
Skin rash 2 – – – –
Peripheral neuropathy 3 3 2 (4) – 2 (4)
Elevated creatinine 1 2 2 (4) – 2 (4)
Elevated aminotransferase 7 4 1 (2) – 1 (2)
Hyperbilirubinemia – 2 1 (2) – 1 (2)
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